Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54


Correlates of alcohol abuse/dependence in early-onset alcohol-using women.

Jenkins MB, Agrawal A, Lynskey MT, Nelson EC, Madden PA, Bucholz KK, Heath AC.

Am J Addict. 2011 Sep-Oct;20(5):429-34. doi: 10.1111/j.1521-0391.2011.00151.x. Epub 2011 Jul 18.


Prospective relationships of ADHD symptoms with developing substance use in a population-derived sample.

Sihvola E, Rose RJ, Dick DM, Korhonen T, Pulkkinen L, Raevuori A, Marttunen M, Kaprio J.

Psychol Med. 2011 Dec;41(12):2615-23. doi: 10.1017/S0033291711000791. Epub 2011 May 20.


Contributions of serotonin in addiction vulnerability.

Kirby LG, Zeeb FD, Winstanley CA.

Neuropharmacology. 2011 Sep;61(3):421-32. doi: 10.1016/j.neuropharm.2011.03.022. Epub 2011 Apr 3. Review.


A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care.

Cheever LW, Kresina TF, Cajina A, Lubran R.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S3-6. doi: 10.1097/QAI.0b013e318209740f.


Individual and network factors associated with non-fatal overdose among rural Appalachian drug users.

Havens JR, Oser CB, Knudsen HK, Lofwall M, Stoops WW, Walsh SL, Leukefeld CG, Kral AH.

Drug Alcohol Depend. 2011 May 1;115(1-2):107-12. doi: 10.1016/j.drugalcdep.2010.11.003. Epub 2010 Dec 3.


High rates of transitions to injecting drug use among Mexican American non-injecting heroin users in San Antonio, Texas (never and former injectors).

Valdez A, Neaigus A, Kaplan C, Cepeda A.

Drug Alcohol Depend. 2011 Apr 1;114(2-3):233-6. doi: 10.1016/j.drugalcdep.2010.09.014. Epub 2010 Nov 13.


Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.

Friedland G.

J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 1:S37-42. doi: 10.1097/QAI.0b013e3181f9c0b6.


Drug treatment as HIV prevention: a research update.

Metzger DS, Woody GE, O'Brien CP.

J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 1:S32-6. doi: 10.1097/QAI.0b013e3181f9c10b. Review.


HIV among people who use drugs: a global perspective of populations at risk.

Stockman JK, Strathdee SA.

J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 1:S17-22. doi: 10.1097/QAI.0b013e3181f9c04c.


Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment.

Arendt M, Munk-Jørgensen P, Sher L, Jensen SO.

Drug Alcohol Depend. 2011 Apr 1;114(2-3):134-9. doi: 10.1016/j.drugalcdep.2010.09.013. Epub 2010 Oct 25.


Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available.

Krupitsky E, Zvartau E, Woody G.

Curr Psychiatry Rep. 2010 Oct;12(5):448-53. doi: 10.1007/s11920-010-0135-5. Review.


Oxford House Recovery Homes: Characteristics and Effectiveness.

Jason LA, Ferrari JR.

Psychol Serv. 2010 May;7(2):92-102.


Retention in naltrexone implant treatment for opioid dependence.

Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen O, Waal H.

Drug Alcohol Depend. 2010 Sep 1;111(1-2):166-9. doi: 10.1016/j.drugalcdep.2010.03.021. Epub 2010 May 31.


Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.

Lucas GM, Chaudhry A, Hsu J, Woodson T, Lau B, Olsen Y, Keruly JC, Fiellin DA, Finkelstein R, Barditch-Crovo P, Cook K, Moore RD.

Ann Intern Med. 2010 Jun 1;152(11):704-11. doi: 10.7326/0003-4819-152-11-201006010-00003.


Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions.

Strathdee SA, Stockman JK.

Curr HIV/AIDS Rep. 2010 May;7(2):99-106. doi: 10.1007/s11904-010-0043-7.


Pain and opioid addiction: what is the connection?

Carinci AJ, Mao J.

Curr Pain Headache Rep. 2010 Feb;14(1):17-21. doi: 10.1007/s11916-009-0086-x. Review.


Pharmacotherapy in the treatment of addiction: methadone.

Kreek MJ, Borg L, Ducat E, Ray B.

J Addict Dis. 2010 Apr;29(2):200-16. doi: 10.1080/10550881003684798.


Long-acting depot formulations of naltrexone for heroin dependence: a review.

Krupitsky EM, Blokhina EA.

Curr Opin Psychiatry. 2010 May;23(3):210-4. doi: 10.1097/YCO.0b013e3283386578. Review.


Supplemental Content

Support Center